New lung fibrosis drug SV001 enters first human safety trial
NCT ID NCT06267183
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new drug called SV001 in 53 healthy Chinese adults to see if it is safe and how the body processes it. Participants receive a single dose of SV001 or a placebo. The goal is to check for side effects and measure drug levels in the blood. This is a first step toward possibly treating idiopathic pulmonary fibrosis, a condition that scars the lungs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SV001
What this could lead to
If this early safety trial succeeds, it could pave the way for a new treatment to control idiopathic pulmonary fibrosis, a serious lung disease.
What could go wrong
This is a very early Phase 1 trial in healthy volunteers, not patients. It only tests safety and dosing, not whether the drug works. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Xuhui District Central Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••